Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 6/20 | 0.71 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.71 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.71 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.61 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.54 |
| ▸ | DPP4 | P27487 | 1/20 | 0.48 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.48 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.48 |
| ▸ | CTSD | P07339 | 1/20 | 0.48 |
| ▸ | AGER | Q15109 | 3/20 | 0.46 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.46 |
| ▸ | TACR1 | P25103 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL22797899 | 0.98 | SLC6A2 (0.70) | SLC6A2SLC6A4SLC6A3KCNH2DCUN1D1 | |
| SCHEMBL3811903 | 0.91 | DCUN1D1 (0.58) | SLC6A2SLC6A4SLC6A3KCNH2DCUN1D1 | |
| Hydrochloric Acid SCHEMBL21410210 | 0.89 | DCUN1D1 (0.57) | SLC6A2SLC6A4SLC6A3KCNH2DCUN1D1 | |
| SCHEMBL6622412 | 0.85 | DCUN1D1 (0.54) | SLC6A2SLC6A4SLC6A3KCNH2DCUN1D1 | |
| SCHEMBL15521608 | 0.84 | DCUN1D1 (0.60) | SLC6A2SLC6A4SLC6A3KCNH2DCUN1D1 | |
| SCHEMBL6633233 | 0.84 | DCUN1D1 (0.60) | SLC6A2SLC6A4SLC6A3KCNH2DCUN1D1 | |
| SCHEMBL27787053 | 0.84 | SLC6A4 (0.61) | SLC6A2SLC6A4SLC6A3KCNH2DCUN1D1 | |
| SCHEMBL4198203 | 0.84 | OPRM1 (0.62) | SLC6A2SLC6A4SLC6A3KCNH2DCUN1D1 | |
| SCHEMBL27787052 | 0.83 | OPRM1 (0.65) | SLC6A2SLC6A4SLC6A3KCNH2DCUN1D1 | |
| SCHEMBL18342235 | 0.81 | SLC6A2 (0.60) | SLC6A2SLC6A4SLC6A3KCNH2CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102056933-B | Thiazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amines as modulators of leukotriene A4 hydrolase | JANSSEN PHARMACEUTICA NV | 2014-09-17 | — | — | CN | claimed |
| CN-103415513-A | Benzodioxane inhibitors of leukotriene production | BOEHRINGER INGELHEIM INT | 2013-11-27 | — | — | CN | claimed |
| CN-102056933-A | Thiazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amines as modulators of leukotriene A4 hydrolase | JANSSEN PHARMACEUTICA NV | 2011-05-11 | — | — | CN | claimed |
| EP-2408454-B1 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP (CA) | 2024-07-24 | — | — | EP | disclosed |
| US-11773090-B2 | Pharmaceutical compounds | HEPTARES THERAPEUTICS LIMITED (GB) | 2023-10-03 | — | — | US | disclosed |
| US-11407719-B2 | Anti-inflammatory agents | RESVERLOGIX CORP. (CA) | 2022-08-09 | — | — | US | disclosed |
| US-20210070716-A1 | ANTI-INFLAMMATORY AGENTS | HEPALINK (HONG KONG) LIMITED (HK) | 2021-03-11 | — | — | US | disclosed |
| US-20210002271-A1 | PHARMACEUTICAL COMPOUNDS | NXERA PHARMA UK LIMITED (GB) | 2021-01-07 | — | — | US | disclosed |
| US-10882828-B2 | Anti-inflammatory agents | RESVERLOGIX CORP. (CA) | 2021-01-05 | — | — | US | disclosed |
| US-10787447-B2 | Pharmaceutical compounds | HEPTARES THERAPEUTICS LIMITED (GB) | 2020-09-29 | — | — | US | disclosed |
| US-20190119222-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP. (CA) | 2019-04-25 | — | — | US | disclosed |
| US-20160137613-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP. (CA) | 2016-05-19 | — | — | US | disclosed |
| US-9238640-B2 | Anti-inflammatory agents | RESVERLOGIX CORP. (CA) | 2016-01-19 | — | — | US | disclosed |
| CN-102056933-B | Thiazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amines as modulators of leukotriene A4 hydrolase | JANSSEN PHARMACEUTICA NV | 2014-09-17 | — | — | CN | disclosed |
| CN-103415513-A | Benzodioxane inhibitors of leukotriene production | BOEHRINGER INGELHEIM INT | 2013-11-27 | — | — | CN | disclosed |
| US-20130281399-A1 | TREATMENT OF DISEASES BY EPIGENETIC REGULATION | RVX THERAPEUTICS INC. (CA) | 2013-10-24 | — | — | US | disclosed |
| CN-102427813-A | Novel anti-inflammatory agents | RESVERLOGIX CORP | 2012-04-25 | — | — | CN | disclosed |
| US-20120040954-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | HEPALINK (HONG KONG) LIMITED (HK) | 2012-02-16 | — | — | US | disclosed |
| CN-102056933-A | Thiazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amines as modulators of leukotriene A4 hydrolase | JANSSEN PHARMACEUTICA NV | 2011-05-11 | — | — | CN | disclosed |
| US-6200989-B1 | ADMINISTERING AS UROKINASE PLASMINOGEN ACTIVATOR ANTAGONISTS, ANTITUMOR AND ANTIMETASTASIS AGENTS | HOFFMANN-LA ROCHE INC. | 2001-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11407719-B2 | Anti-inflammatory agents | VCAM1, ICAM1, IL6 | SLC6A2 4441/4885SLC6A4 4521/4885SLC6A3 4538/4885 |
| US-20160137613-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | VCAM1, ICAM1, IL6 | SLC6A2 4454/4885SLC6A4 4514/4885SLC6A3 4539/4885 |
| US-20130281399-A1 | TREATMENT OF DISEASES BY EPIGENETIC REGULATION | PHKB, BAZ2A, EP300 | SLC6A2 4348/4885SLC6A4 4403/4885SLC6A3 4125/4885 |
| US-10882828-B2 | Anti-inflammatory agents | VCAM1, ICAM1, IL6 | SLC6A2 4441/4885SLC6A4 4521/4885SLC6A3 4538/4885 |
| US-20210070716-A1 | ANTI-INFLAMMATORY AGENTS | VCAM1, ICAM1, IL6 | SLC6A2 4441/4885SLC6A4 4521/4885SLC6A3 4538/4885 |
| US-11773090-B2 | Pharmaceutical compounds | CHRM1, CHRM2, CHRM4 | SLC6A2 1197/4885SLC6A4 1162/4885SLC6A3 1264/4885 |
| US-20210002271-A1 | PHARMACEUTICAL COMPOUNDS | CHRM1, CHRM2, CHRM4 | SLC6A2 1197/4885SLC6A4 1162/4885SLC6A3 1264/4885 |
| US-20190119222-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | VCAM1, ICAM1, IL6 | SLC6A2 4454/4885SLC6A4 4514/4885SLC6A3 4539/4885 |
| US-10787447-B2 | Pharmaceutical compounds | CHRM1, CHRM2, CHRM4 | SLC6A2 1197/4885SLC6A4 1162/4885SLC6A3 1264/4885 |
| US-20120040954-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | VCAM1, ICAM1, IL6 | SLC6A2 4454/4885SLC6A4 4514/4885SLC6A3 4539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.